Melphalan

Alkylating Agent
DB01042
Approved Indication

For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palli

0 Targets
0 Resistance Mutations
3 References
3D Structure No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases (primarily at the N-7 position of guanine and to a lesser extent, at the N-3 position of adenine), forming monoadducts and resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Details
DrugBank ID DB01042 ↗
Approval Date 2009-10-27
Molecular Weight 305.2 g/mol
Drug Class Alkylating Agent
ATC Codes L01AA03
Synonyms L-PAM, L-Phenylalanine mustard, L-Sarcolysine
SMILES
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
ADMET Profile
Computing properties…